SAGE Therapeutics

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SAGE Therapeutics poised for Zuranolone launch in 2023, overcoming challenges

SAGE Therapeutics showcased strong financial performance and promising developments with Zuranolone, positioning the drug favorably for potential launch in 2023.
While facing challenges such as enrollment issues and DEA scheduling impacts, the company is leveraging opportunities in commercialization strategies and post-marketing studies to enhance Zuranolone's market presence.
Overall, Zuranolone's rapid and durable effects, alignment with current treatment practices, and targeted commercialization approach present a compelling opportunity for SAGE Therapeutics in the mental health treatment landscape.
By addressing challenges effectively and capitalizing on opportunities, SAGE Therapeutics is poised to make a significant impact in advancing treatments for mood disorders and improving patient outcomes.

Sage Therapeutics reports strong Q1 performance and eyes market expansion

Sage Therapeutics had a strong Q1 2023, focusing on brain health medicines and preparing for zuranolone's launch.
The company's financial position is solid, with growth opportunities in pipeline programs and proactive payer engagements.
Challenges include regulatory uncertainties and competition, but Sage is well-positioned to capitalize on market demand.
Opportunities lie in expanding product indications, proactive agreements with payers, and learning from competitors for strategic advantage.

SAGE Therapeutics to Launch Zurzuvae for Postpartum Depression, Overcomes FDA Setback

SAGE Therapeutics is poised to launch Zurzuvae for postpartum depression, leveraging its financial strength and clinical success. While facing challenges in MDD, the company is strategically adapting to focus on PPD and enhance operational efficiency. Opportunities lie in collaborations, pricing strategies, and addressing the significant market need for PPD treatments.

SAGE Therapeutics advances women's health with ZURZUVAE approval

SAGE Therapeutics navigates financial challenges while advancing innovative treatments for women's health.
ZURZUVAE's approval and commercialization plans present opportunities in a significant market segment.
Strategic focus on engagement, access, and market positioning key to ZURZUVAE's success.
Pipeline advancements and collaboration efforts position SAGE for future growth and impact.

SAGE Therapeutics excels with ZURZUVAE launch, poised for continued growth

SAGE Therapeutics had a strong performance in 2023, driven by the successful launch of ZURZUVAE and positive early market reception.
While facing challenges in data tracking and market competition, the company's focus on innovation and patient access presents growth opportunities.
With a robust pipeline and strategic initiatives in place, SAGE is well-positioned to maintain momentum and drive further success in the brain health space.

SAGE Therapeutics reports strong Zurzuvae launch amidst Parkinson's study setback

SAGE Therapeutics is navigating challenges from the PRECEDENT study while capitalizing on Zurzuvae's successful launch for PPD.
The company's pipeline progress and commitment to addressing cognitive disorders in neurodegenerative diseases showcase a strong focus on brain health.
Collaborative efforts with Biogen, strong payer coverage, and positive market feedback position Zurzuvae as a frontline treatment for PPD.
Strategic initiatives to educate prescribers, expand market reach, and refine study designs present promising growth opportunities for SAGE.

SAGE Therapeutics faces setbacks but sees success with ZURZUVAE in Q2

SAGE Therapeutics navigates setbacks with SAGE-324 study closure but sees success with ZURZUVAE in PPD treatment. Strong financial foundation and commitment to brain health initiatives position the company for future growth.

SAGE Therapeutics focuses on Zurzuvae for PPD treatment success

SAGE Therapeutics prioritizes Zurzuvae for PPD, showing strong revenue growth and prescription uptake
Challenges include discontinuation of certain programs and mixed results in clinical studies
Opportunities lie in focusing resources, upcoming study results, and strategic program ownership
Overall, SAGE's reorganization reflects a strategic shift towards maximizing Zurzuvae's potential

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].

SAGE ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sage Therapeutics, Inc.

Sage Therapeutics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SAGE

NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].

ATTENTION Sage Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SAGE

An Investigation Has Commenced on Behalf of Sage Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SAGE Losses.

Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Ashley Kaplowitz - Vice President-Investor Relations & Capital Markets Barry Greene - Chief Executive Officer & Member-Board of Directors Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - JPMorgan Ritu Baral - TD Cowen Laura Chico - Wedbush Securities Paul Matteis - Stifel Jay Olson - Oppenheimer Ami Fadia - Needham Brian Abrahams - RBC Capital Markets George Farmer - Scotiabank Sumant Kulkarni - Canaccord Yatin Suneja - Guggenheim Douglas Tsao - HC Wainwright Operator Good morning, and welcome to Sage Therapeutics First Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Sage Therapeutics, Inc. (SAGE) Q1 2024 Earnings Call Transcript

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.80 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to loss of $2.46 per share a year ago.

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024. “The launch of ZURZUVAE is off to an encouraging start, reflected in the strong performance in the first full quarter of the launch. We are seeing increasing demand among HCPs, particularly OBGYNs, and hearing inspiring success stories.

Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.

Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal

Children's Place

Depending on who you ask, a recession is either right around the corner or the stock market is ready to rattle off a seismic bull run.

2 Well-Priced Stocks Staging Big Swings Today

Sage Therapeutics Inc. shares dropped 17% early Wednesday after the company said its experimental treatment for mild cognitive impairment in patients with Parkinson's disease fell flat in a clinical trial.

Sage Therapeutics' stock plunges as Parkinson's drug trial disappoints

Sage Therapeutics said Wednesday its Parkinson's treatment failed in a midstage study, and Sage stock collapsed to a record low.

Sage Therapeutics Hammered After Parkinson's Drug Misses The Mark

Sage Therapeutics said on Wednesday it will stop development of its experimental drug to treat Parkinson's disease after it failed a mid-stage study, sending the company's shares down 4% before the bell.

Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson's Disease (PD). The PRECEDENT Study did not meet its primary endpoint of demonstrating statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on.

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion o.

Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024

Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock?

Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference (Boston, MA): fireside chat on Tuesday, March 5, 2024 at 2:50 p.m. ET. Stifel 2024 Virtual CNS Days (Virtual): fireside chat on Tuesday, March 19, 2024 at 1:30 p.m. ET. A live webcast of ea.

Sage Therapeutics to Present at Upcoming March Investor Conferences

Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae.

Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates

SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023. “2023 was a pivotal year for Sage, with key accomplishments achieved across our pipeline, culminating with the recent encouraging launch of ZURZUVAE, the first-and-only once daily oral treatment for adults with postpa.

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, February 14, 2024 at 8:00 a.m. ET to review fourth quarter and full year 2023 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available followi.

Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that Chief Executive Officer Barry Greene will discuss the Company's key business drivers for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. As part of this presentation, Mr. Greene will discuss commercialization of ZURZUVAE™ (zuranolone), the first and only once-daily 14-day or.

Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the retirement of Kevin Starr from the company's board of directors. Geno Germano has assumed the role of Chair of the Board of Directors. Mr. Starr led the early efforts to launch Sage Therapeutics, served as CEO prior to the company's initial public offering, and served as Chair of the Board since Sage went public in.

News for SAGE Therapeutics Stock (SAGE)